Insilico Medicine reports positive Phase IIa results for ISM001-055 for the treatment of idiopathic pulmonary fibrosis (IPF) designed using generative AI

Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055, a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase). ISM001-055 was designed using a unique AI platform to…


FDA approves Rybrevant for advanced lung cancer

The FDA approved the drug amivantamab-vmjw in combination with standard chemotherapy for the treatment of certain adults with non-small cell lung cancer, according to a press release by Johnson & Johnson. The indication applies to adults with locally advanced or metastatic…



Is human lifespan limited by a single molecule?

A paper recently published by Dr. Ádám Sturm and Dr. Tibor Vellai from Eötvös Loránd University uncovers the critical role of mitochondrial DNA, as well as the different ways in which it can be modified and how these modifications impact…